Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) has issued an announcement.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has announced its annual results for the year ending December 31, 2024, showing a significant decline in revenue and profit compared to previous years. The company’s revenue decreased to RMB 709,405,000 from RMB 850,733,000 in 2023, and profit before income tax dropped to RMB 5,458,000 from RMB 97,528,000. This downturn reflects challenges in the biopharmaceutical sector, potentially impacting the company’s market position and stakeholder confidence.
More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. operates in the biopharmaceutical industry, focusing on the development, manufacturing, and sale of pharmaceutical products. The company is primarily engaged in creating innovative drugs and therapies, targeting various medical needs and enhancing healthcare solutions.
See more insights into 1349 stock on TipRanks’ Stock Analysis page.